A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
In a prospective, open-label, assessor-blind, randomised parallel group study the efficacy and safety of Hemabate (Pharmacia-Upjohn Pharmaceuticals, Milton Keynes, Buckinghamshire) an analogue of 15-methyl-prostaglandin (PGF2alpha) analogue was compared with Syntometrine (Alliance Pharmaceuticals, Chippenham, Wilts) the standard combination of ergometrine and syntocinon used for the active management of the third stage of labour and the prevention of primary postpartum haemorrhage (PPH). The study was set in a district general hospital with approximately 4,000 deliveries annually. The study was discontinued at the time of the interim analysis because of unacceptable gastrointestinal side effects. At the time of the interim analysis, a total of 529 women had completed the study with 263 randomised to receive PGF2alpha and 266 to receive ergometrine and syntocinon. In a pre-specified subgroup analysis, women delivered vaginally were further subdivided into those considered to be at high or low risk of primary PPH. The measured blood loss and incidence of PPH was similar in both treatment groups whether delivered by caesarean section or vaginally independent of whether women were considered to be at high or low risk. Adverse gastrointestinal events were recorded more often in the Hemabate group. The most common symptom was diarrhoea which occurred in 21% of women who received Hemabate compared to only 0.8% of Syntometrine users. PGF2alpha is as effective as Syntometrine in the prophylaxis of primary PPH in all groups studied but there was a statistically significantly increased risk of diarrhoea among users of PGF2alpha.
Lamont
R F
RF
Department of Obstetrics and Gynaecology, Northwick Park and St Mark's NHS Trust Harrow, Middlesex, United Kingdom. rflamont@AOL.com
Morgan
D J
DJ
Logue
M
M
Gordon
H
H
D000328:Adult; D001794:Blood Pressure; D001827:Body Height; D001835:Body Weight; D002260:Carboprost / Q000009:adverse effects* / Q000494:pharmacology*; D002585:Cesarean Section; D015237:Dinoprost / Q000009:adverse effects / Q000494:pharmacology; D004198:Disease Susceptibility; D004338:Drug Combinations; D004874:Ergonovine / Q000009:adverse effects* / Q000494:pharmacology*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010121:Oxytocin / Q000009:adverse effects* / Q000494:pharmacology*; D010298:Parity; D006473:Postpartum Hemorrhage / Q000517:prevention & control*; D011247:Pregnancy; D011897:Random Allocation; D016037:Single-Blind Method; D014325:Tromethamine / Q000009:adverse effects* / Q000494:pharmacology*
D004338:Drug Combinations; D014325:Tromethamine; C038346:syntometrine; D010121:Oxytocin; D002260:Carboprost; D015237:Dinoprost; C062843:carboprost tromethamine; D004874:Ergonovine